A thrombopoietin antagonist is capable of affecting stem and progenitor cells of patients with myelofibrosis

Xiaolin Wang, David Haylock, Cing Siang Hu, Goar Mosoyan, D.A. Winkler, Ronald Hoffman

Research output: Contribution to journalArticleOther

Abstract

Aberrant thrombopoietin (TPO)/MPL signaling has been hypothesized to contribute to the pathogenesis of myelofibrosis (MF). Agents that would be capable of inhibiting this signaling pathway are possible novel therapeutic agents that might be effective for MF treatment. A peptide antagonist of TPO, LCP4, has been created which is highly antagonistic to CB CD34+ cell proliferation and differentiation induced by TPO. In this report we examined the effect of LCP4 on the proliferation of MF CD34+ cells and their differentiation to megakaryocytes (Mk).
Original languageEnglish
Pages (from-to)819
Number of pages1
JournalBlood
Volume124
Issue number21
Publication statusPublished - 2014

Cite this